Reinhold Munker - University of Kentucky

Education/Academic qualification

Doctor of Medicine, Unversitat Erlange-Nurnberg (Germany)

1979

3 Finished
6 Active

23-NHL-30-OP (ONO-4059-09): An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma (PCNSL)
Munker, R.
Ono Pharmaceutical
7/24/23 → 7/24/25
Project: Research project
22-LEUK-21-NP (CABL001AUS08): A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase-Chronic Myelogenous Leukemia (ASC2ESCALATE)
Munker, R.
Novartis (domestic)
2/3/23 → 12/31/28
Project: Research project
22-HEM-19-MSD: A Phase 3 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-Refractory, Relapsed or Refractory Classical Hodgkin Lymphoma
Munker, R.
Merck Sharp & Dohme Corporation
1/23/23 → 11/2/25
Project: Research project
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naive Mantle Cell Lymphoma (BRUIN MCL-321)
Munker, R.
IQVIA RDS Incorporated
9/29/21 → 6/28/25
Project: Research project
Phase III, Multi-Center, Open-Label, Randomized Study Of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia In Chronic Phase
Munker, R.
Novartis (domestic)
8/17/21 → 10/30/25
Project: Research project